دورية أكاديمية
Measuring interictal burden among people affected by migraine: a descriptive survey study
| العنوان: | Measuring interictal burden among people affected by migraine: a descriptive survey study |
|---|---|
| المؤلفون: | Lena T. Hubig, Timothy Smith, Emma Williams, Lauren Powell, Karissa Johnston, Linda Harris, Gilbert L’Italien, Vladimir Coric, Andrew J. Lloyd, Siu Hing Lo |
| المصدر: | The Journal of Headache and Pain, Vol 23, Iss 1, Pp 1-9 (2022) |
| بيانات النشر: | BMC, 2022. |
| سنة النشر: | 2022 |
| المجموعة: | LCC:Medicine |
| مصطلحات موضوعية: | Migraine, Patient-reported outcome, Questionnaire, Health-related quality of life, Disease burden, Medicine |
| الوصف: | Abstract Background Previous research has extensively documented the impact of migraine episodes (‘ictal’) on patients’ health-related quality of life. Few studies have looked at the impact of migraine on migraine-free days (‘interictal’). This study was designed to describe interictal burden of migraine in a mixed group of people affected by migraine and to explore patient characteristics associated with interictal burden. Methods People with migraine in the United States (US) and Germany were recruited for a cross-sectional online survey, including a subgroup treated with calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb). The survey included the Migraine Interictal Burden Scale (MIBS-4), Headache Impact Test (HIT-6), and items measuring patient demographics, clinical and treatment background. Data were analyzed using descriptive statistics and linear regression. Results Five hundred six people with migraine completed the survey (US: n = 257; Germany: n = 249), of whom 195 had taken a CGRP mAb for three or more months. Participants had a mean of 8.5 (SD = 6.4) Monthly Migraine Days (MMD) and 10.4 (SD = 7.1) Monthly Headache Days (MHD). The mean MIBS-4 score was 6.3 (SD = 3.4), with 67% reporting severe interictal burden (MIBS-4: ≥5). The mean HIT-6 score was 65.3 (SD = 6.0), with 86% reporting severe migraine impact (HIT-6: ≥60). MIBS-4 was correlated with the HIT-6 (r = 0.37), MMD and MHD (both r = 0.27). The HIT-6, MMD, MHD, CGRP mAb treatment, and depression all had an independent positive association with the MIBS-4. Conclusion Two-thirds of the study sample reported substantial interictal burden. Whilst interictal burden was associated with migraine frequency and impact of migraine attacks, study results also show it represented a distinct aspect of the overall disease burden. Study findings further indicate unique associations between interictal burden and depression. A unique positive association between interictal burden and CGRP mAb treatment suggests a remaining unmet need among people affected by migraine treated with CGRP mAb. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1129-2369 1129-2377 |
| العلاقة: | https://doaj.org/toc/1129-2369Test; https://doaj.org/toc/1129-2377Test |
| DOI: | 10.1186/s10194-022-01467-z |
| الوصول الحر: | https://doaj.org/article/5bf1286b09f94b7f978b3f9130198fccTest |
| رقم الانضمام: | edsdoj.5bf1286b09f94b7f978b3f9130198fcc |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 11292369 11292377 |
|---|---|
| DOI: | 10.1186/s10194-022-01467-z |